Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

The therapy showed a two-point reduction in total PANSS score at week six against placebo with atypical antipsychotic.

The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

US pharma major Bristol Myers Squibb (NYSE: BMY) saw its shares fall 4% in after-hours trading on Tuesday, after it announced ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been recommended by the National ...

The integration of digital technology is transforming the EV battery electrical testing equipment market, facilitating ...

A New York City federal court has dismissed a proposed class-action lawsuit against Bristol Myers Squibb that accused the ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion ...

Music superstar and three-time GRAMMY-Award winner Tim McGraw has been named the headliner in a special pregame concert event ...

Specialist reinsurance broker BMS Group has appointed Jean-Jacques Henchoz as its board chairman, with the role to be handed ...

CSIO has announced that Gore Mutual Insurance Company has received its eDocs Certification, confirming that the insurer’s ...